These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
456 related articles for article (PubMed ID: 14973504)
1. Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias. Vandenberghe P; Wlodarska I; Michaux L; Zachée P; Boogaerts M; Vanstraelen D; Herregods MC; Van Hoof A; Selleslag D; Roufosse F; Maerevoet M; Verhoef G; Cools J; Gilliland DG; Hagemeijer A; Marynen P Leukemia; 2004 Apr; 18(4):734-42. PubMed ID: 14973504 [TBL] [Abstract][Full Text] [Related]
2. The hypereosinophilic syndrome: fluorescence in situ hybridization detects the del(4)(q12)-FIP1L1/PDGFRA but not genomic rearrangements of other tyrosine kinases. La Starza R; Specchia G; Cuneo A; Beacci D; Nozzoli C; Luciano L; Aventin A; Sambani C; Testoni N; Foppoli M; Invernizzi R; Marynen P; Martelli MF; Mecucci C Haematologica; 2005 May; 90(5):596-601. PubMed ID: 15921374 [TBL] [Abstract][Full Text] [Related]
3. FIP1L1-PDGFRalpha alone or with other genetic abnormalities reveals disease progression in chronic eosinophilic leukemia but good response to imatinib. Wang LN; Pan Q; Fu JF; Shi JY; Jin J; Li JM; Hu J; Zhao WL; Chen Z; Chen SJ Chin Med J (Engl); 2008 May; 121(10):867-73. PubMed ID: 18706197 [TBL] [Abstract][Full Text] [Related]
4. Clinical characteristics of patients with chronic eosinophilic leukaemia (CEL) harbouring FIP1L1-PDGFRA fusion transcript--results of Polish multicentre study. Helbig G; Moskwa A; Hus M; Piszcz J; Swiderska A; Urbanowicz A; Całbecka M; Gajkowska J; Seferyńska I; Hałasz M; Woszczyk D; Markiewicz M; Krzemień S Hematol Oncol; 2010 Jun; 28(2):93-7. PubMed ID: 19728396 [TBL] [Abstract][Full Text] [Related]
5. Successful imatinib treatment of cardiac involvement of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia followed by severe hepatotoxicity. Arai A; Yan W; Wakabayashi S; Hayashi S; Inazawa J; Miura O Int J Hematol; 2007 Oct; 86(3):233-7. PubMed ID: 17988989 [TBL] [Abstract][Full Text] [Related]
6. A novel FIP1L1-PDGFRA mutant destabilizing the inactive conformation of the kinase domain in chronic eosinophilic leukemia/hypereosinophilic syndrome. Salemi S; Yousefi S; Simon D; Schmid I; Moretti L; Scapozza L; Simon HU Allergy; 2009 Jun; 64(6):913-8. PubMed ID: 19210352 [TBL] [Abstract][Full Text] [Related]
7. FIP1L1-PDGFR alpha, a therapeutic target for the treatment of chronic eosinophilic leukemia. Cools J Verh K Acad Geneeskd Belg; 2005; 67(3):169-76. PubMed ID: 16089297 [TBL] [Abstract][Full Text] [Related]
8. A single weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukaemia in FIP1L1-PDGFRA-expressing patients. Helbig G; Stella-Hołowiecka B; Majewski M; Całbecka M; Gajkowska J; Klimkiewicz R; Moskwa A; Grzegorczyk J; Lewandowska M; Hołowiecki J Br J Haematol; 2008 Apr; 141(2):200-4. PubMed ID: 18307562 [TBL] [Abstract][Full Text] [Related]
9. FIP1L1-PDGFRA in chronic eosinophilic leukemia and BCR-ABL1 in chronic myeloid leukemia affect different leukemic cells. Crescenzi B; Chase A; Starza RL; Beacci D; Rosti V; Gallì A; Specchia G; Martelli MF; Vandenberghe P; Cools J; Jones AV; Cross NC; Marynen P; Mecucci C Leukemia; 2007 Mar; 21(3):397-402. PubMed ID: 17215855 [TBL] [Abstract][Full Text] [Related]
10. Detection of FIP1L1-PDGFRA fusion by FISH. Ma ES; Wong KF; Wong CL; Siu LL Br J Haematol; 2007 Aug; 138(3):279. PubMed ID: 17542982 [No Abstract] [Full Text] [Related]
11. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Pardanani A; Ketterling RP; Brockman SR; Flynn HC; Paternoster SF; Shearer BM; Reeder TL; Li CY; Cross NC; Cools J; Gilliland DG; Dewald GW; Tefferi A Blood; 2003 Nov; 102(9):3093-6. PubMed ID: 12842979 [TBL] [Abstract][Full Text] [Related]
12. A case of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia with a rare FIP1L1 breakpoint. Lambert F; Heimann P; Herens C; Chariot A; Bours V J Mol Diagn; 2007 Jul; 9(3):414-9. PubMed ID: 17591942 [TBL] [Abstract][Full Text] [Related]
13. [Characteristics of cytogenetics and molecular biology in patients with eosinophilia]. Qu SQ; Ai XF; Li CW; Li QH; Xu ZF; Qin TJ; Zhang Y; Xiao ZJ Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Oct; 20(5):1216-20. PubMed ID: 23114151 [TBL] [Abstract][Full Text] [Related]
14. The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management. Gotlib J; Cools J; Malone JM; Schrier SL; Gilliland DG; Coutré SE Blood; 2004 Apr; 103(8):2879-91. PubMed ID: 15070659 [TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study. Metzgeroth G; Walz C; Erben P; Popp H; Schmitt-Graeff A; Haferlach C; Fabarius A; Schnittger S; Grimwade D; Cross NC; Hehlmann R; Hochhaus A; Reiter A Br J Haematol; 2008 Dec; 143(5):707-15. PubMed ID: 18950453 [TBL] [Abstract][Full Text] [Related]
16. Pure red cell aplasia associated with imatinib-treated FIP1L1-PDGFRA positive chronic eosinophilic leukemia. Tanaka H; Iwato K; Asou H; Kimura A Intern Med; 2010; 49(12):1195-200. PubMed ID: 20558942 [TBL] [Abstract][Full Text] [Related]
17. Identification of a novel imatinib responsive KIF5B-PDGFRA fusion gene following screening for PDGFRA overexpression in patients with hypereosinophilia. Score J; Curtis C; Waghorn K; Stalder M; Jotterand M; Grand FH; Cross NC Leukemia; 2006 May; 20(5):827-32. PubMed ID: 16498388 [TBL] [Abstract][Full Text] [Related]
18. Systemic mastocytosis (SM) associated with chronic eosinophilic leukemia (SM-CEL): detection of FIP1L1/PDGFRalpha, classification by WHO criteria, and response to therapy with imatinib. Florian S; Esterbauer H; Binder T; Müllauer L; Haas OA; Sperr WR; Sillaber C; Valent P Leuk Res; 2006 Sep; 30(9):1201-5. PubMed ID: 16406018 [TBL] [Abstract][Full Text] [Related]
19. FIP1L1-PDGFRA positive chronic eosinophilic leukaemia and associated central nervous system involvement. Williams C; Kalra S; Nath U; Bown N; Wilson V; Wilkins BS; Neylon AJ J Clin Pathol; 2008 May; 61(5):677-80. PubMed ID: 18256119 [TBL] [Abstract][Full Text] [Related]